News

Public · Published

Buy Paras Healthcare; target of Rs 900: Choice Institutional Equities

Choice Institutional Equities initiated coverage on Paras Healthcare with a BUY rating and a target price of Rs 900, implying about 30% upside. The report says six core specialties generated roughly 75% of the company's FY26 revenue.

Published:

Updated:

What happened

Choice Institutional Equities initiated coverage on Paras Healthcare with a BUY rating and a target price of Rs 900, implying about 30% upside. The report says six core specialties generated roughly 75% of the company's FY26 revenue.

Confirmed

Global impact / market context

A narrow set of specialties producing most revenue means Paras Healthcare depends heavily on heart, cancer, brain, stomach, bone and kidney care. That focus can support pricing and profit per sale, but weakness in any one specialty could hurt results.

Analyst inference

The Rs 900 target rests on a discounted cash flow valuation, which estimates future cash flows and adjusts them for time and risk. The report also cites an implied valuation multiple of 14 times earnings before interest, tax, depreciation and amortization.

Analyst inference

What to watch

  1. Watch whether occupancy, the share of beds in use, improves and patient numbers rise, since the report projects these factors will drive revenue productivity. Confirmed
  2. Track revenue contribution from complex procedures, as a higher share could lift revenue per patient and strengthen earnings resilience. Analyst inference
  3. Monitor execution in underserved North India markets, because the report presents expansion there as growth headroom that supports the BUY rating. Proposed

Evidence

  • Original source link unavailable